Share This Page
SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sodium Sulfate, Magnesium Sulfate And Potassium Chloride, and what generic alternatives are available?
Sodium Sulfate, Magnesium Sulfate And Potassium Chloride is a drug marketed by Lupin and is included in one NDA.
The generic ingredient in SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE is magnesium sulfate; potassium chloride; sodium sulfate. There are one hundred and forty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the magnesium sulfate; potassium chloride; sodium sulfate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE?
- What are the global sales for SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE?
- What is Average Wholesale Price for SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE?
Summary for SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin | SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE | magnesium sulfate; potassium chloride; sodium sulfate | TABLET;ORAL | 216095-001 | May 28, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Investment Scenario and Fundamentals Analysis for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride (Combination Oral Laxative)
Executive summary
- Sodium sulfate, magnesium sulfate and potassium chloride is a commonly used oral bowel-prep combination with a commoditized competitive landscape and limited patent runway risk.
- Investment fundamentals hinge on (1) regulatory interchangeability and labeling position, (2) manufacturing scale and quality systems, (3) price and payer contracting in endoscopy/prep channels, and (4) exposure to FDA enforcement and supply reliability.
- For new entrants, the economics typically depend more on manufacturing execution and distribution leverage than on new IP creation, because the market is dominated by established, long-sold, non-biologic small-molecule generics.
- For incumbents or specialty investors, value is tied to continuity of supply, tight formulation/process control, and defensible differentiation through packaging, labeling, and manufacturing know-how rather than active-substance exclusivity.
What is sodium sulfate, magnesium sulfate and potassium chloride used for and how is it priced?
Featured snippet answer: It is used as an oral bowel preparation for colon cleansing prior to diagnostic and therapeutic procedures such as colonoscopy; pricing is largely driven by generic competition, channel contracting, and pack-size economics.
Indications and clinical role
- Typical use case: bowel cleansing prior to colonoscopy and related GI procedures.
- Operational determinant: split-dose regimens and patient tolerability drive adherence and downstream procedural scheduling.
Key demand drivers
- GI procedure volume: colonoscopy incidence and screening adherence.
- Endoscopy capacity: scheduling practices and prep adherence affect throughput.
- Patient mix: comorbidity burden influences tolerability and substitution behavior across bowel prep products.
Pricing dynamics
- Generic-led price compression is typical for older, widely available bowel prep actives.
- Net pricing is channel-specific: hospital systems, ambulatory surgery centers, pharmacy benefit plans, and patient out-of-pocket tiers.
- Pack-size strategy matters: multiple-dose formats, day-of-procedure vs prior-day instructions, and pill-to-liquid handling all influence formulary preference.
What is the competitive landscape for bowel prep products containing sulfate and chloride salts?
Featured snippet answer: Competition is dominated by multi-source generic formulations and branded comparators that differentiate by regimen, taste, volume, and instructions more than by core actives.
Comparative product set (category-level)
Common comparator classes include:
- Other sulfate-based regimens (e.g., sodium phosphate combinations where marketed, and sulfate-heavy oral solutions)
- Magnesium- and/or osmotic-based regimens
- Low-volume and tablet-based options (where available in the market)
- PEG-electrolyte and similar osmotic solutions
How competition plays out commercially
- Formulary inclusion: payer and hospital formularies shift based on tolerability, adverse event profile management, and nurse/clinic workflow.
- Physician preference: often regimen-specific and influenced by staff familiarity.
- Substitution: pharmacy substitution is routine when multiple AB-rated products exist.
Barriers to entry
- Manufacturing and QA: consistent impurity control, electrolyte balance, and stability.
- Distribution reliability: bowel preps have demand spikes around procedure scheduling.
- Regulatory discipline: compliance with current good manufacturing practice (CGMP) and post-market safety monitoring.
What patents protect sodium sulfate, magnesium sulfate and potassium chloride?
Featured snippet answer: Core compositions and earlier process patents for these older small-molecule salts are largely time-barred in most major markets; current competitive protection, if any, tends to focus on specific formulations, packaging, manufacturing methods, and labeling.
Patent estate reality check for older salts
- These actives are simple inorganic salts with long historical use.
- Competitive differentiation tends to rely on:
- Specific ratios and solution preparation processes
- Stability and shelf-life improvements via manufacturing/process controls
- Packaging and delivery systems (e.g., dosing regimen kits)
Investment implication
- Investors should model as “low-margin IP” unless a specific portfolio remains active in a given jurisdiction for a specific dosage form or process.
When does exclusivity end for sodium sulfate, magnesium sulfate and potassium chloride products?
Featured snippet answer: For older bowel prep products with long-standing marketed status, exclusivity typically has ended; ongoing market presence is usually sustained by generic readiness and regulatory maintainers, not by active exclusivity.
How to think about exclusivity in practice
- Expect limited or no composition-level exclusivity.
- Any remaining regulatory exclusivity (data protection, marketing exclusivity) is usually product-specific and time-limited.
- Competitive pressure tends to rise quickly after final exclusivity windows close, unless there is a manufacturing constraint or heightened safety-driven labeling restrictions.
Investment implication
- For entry or expansion, treat the base-case as “genericized demand” with pricing power constrained by multi-source availability.
What is the Orange Book status of sodium sulfate, magnesium sulfate and potassium chloride products?
Featured snippet answer: Orange Book coverage is typically populated by multiple listed small-molecule products with AB rating equivalence, reflecting multi-source generic competition.
What Orange Book listings indicate for investors
- Number of competing products: higher counts usually correlate with price compression.
- Patent listing types: product-specific listed patents can exist, but for inorganic salts they are less likely to block entry at scale unless tied to specific processes.
Investment implication
- If multiple AB-rated products exist with no blocking patents, the commercial strategy should focus on execution and contracting rather than IP-driven market entry timing.
How many Paragraph IV challenges exist for bowel prep salt combinations and what do they signal?
Featured snippet answer: Paragraph IV activity in this class is typically limited relative to high-value oncology or specialty drugs; where it occurs, it signals market entry intent under generic regulation, not structural brand value.
How to interpret “generic challenge” as a market signal
- More challenges: indicates ongoing entrants see windows to price at scale.
- Fewer challenges: can indicate existing supply dominance and limited incremental profitability.
Investment implication
- In this class, treat Paragraph IV intensity as a “supply/demand and manufacturing economics” proxy more than an IP-driven growth proxy.
What generic entry risks exist for new sodium sulfate, magnesium sulfate and potassium chloride launches?
Featured snippet answer: The main risks are not IP blocking so much as manufacturing readiness, regulatory acceptance, supply continuity, and reimbursement/formulary positioning.
Practical generic launch risk map
- Manufacturing validation and impurity control
- Batch-to-batch consistency of electrolyte concentration
- Stability under storage conditions
- Labeling and patient instruction compliance
- Adverse event monitoring and causality disputes affecting physician acceptance
Investment implication
- New capacity must be built with quality-by-design and robust change control to avoid supply interruptions that can be commercially fatal in competitive GI channels.
How does sodium sulfate, magnesium sulfate and potassium chloride compare with PEG-electrolyte and other bowel preps?
Featured snippet answer: Comparative performance is typically about tolerability, volume burden, patient adherence, and electrolyte safety management, with regimen convenience often driving substitution between classes.
What matters for commercial adoption
- Tolerability: nausea, vomiting, dehydration symptoms, and adherence to split dosing.
- Safety considerations: electrolyte disturbances and contraindication management in renal impairment or other high-risk patients.
- Workflow: clinic readiness for patient instruction, kit handling, and timing.
Investment implication
- Differentiation must be demonstrated in real-world adherence and procedural completion outcomes, or secured through payer contracting and channel relationships.
What formulation and manufacturing patents matter most for bowel prep salt products?
Featured snippet answer: Where patents exist, they more commonly target formulation/process constraints rather than composition-level chemistry, making manufacturing excellence a dominant driver of competitiveness.
Typical patentable angles (category-level)
- Stabilization and impurity reduction during dissolution and shelf-life
- Process improvements that reduce variability or degradation products
- Packaging technologies that control moisture exposure, dosing accuracy, and patient handling
Investment implication
- A company can win by outperforming on manufacturing KPIs even without strong composition IP, because substitution is easy but supply reliability and quality performance are not.
What FDA regulatory status considerations drive risk and cost for these products?
Featured snippet answer: Risk is dominated by CGMP compliance, labeling adequacy, adverse-event signal monitoring, and manufacturing inspection outcomes rather than biologics-style pathway complexity.
Key regulatory cost drivers
- Facility inspections and remediation costs
- Variations and change control for manufacturing sites and suppliers
- Lot release testing systems
- Pharmacovigilance operations for GI adverse events and electrolyte imbalance reports
Investment implication
- Allocate capex and opex to QA systems and regulatory readiness; regulatory events can create supply stoppages that swing revenue quickly in commodity categories.
What litigation affects sodium sulfate, magnesium sulfate and potassium chloride products?
Featured snippet answer: In commodity bowel preps, litigation more often centers on generic labeling disputes, patent-specific challenges when they exist, and product quality or labeling adequacy rather than sustained composition IP battles.
Litigation categories investors should map
- Patent disputes tied to formulation/process claims, if any remain
- FDA enforcement actions (warning letters, consent decrees)
- Product liability cases related to bowel prep adverse events (often fact-specific)
- Labeling and instructions disputes in the context of contraindications
Investment implication
- Legal exposure tends to be manageable compared with high-IP therapeutic areas, but supply and quality events can create outsized financial impact.
How strong is the patent estate for sodium sulfate, magnesium sulfate and potassium chloride, and is it investable?
Featured snippet answer: Patent strength is generally weak for blocking entry because the actives are old, but investability can still be real through manufacturing moats and distribution leverage.
Strength scoring framework (practical for this category)
- Composition novelty: low likelihood for active strong claims
- Process/formulation: possible, but usually narrower and easier to design around
- Enforcement history: often low relative to specialty drugs unless specific patents remain active
- Remaining term by jurisdiction: typically limited
Investment implication
- Model valuation on scale efficiency, throughput, and contracting rather than patent monetization.
Investment scenario: incumbent scaling vs. generic entry vs. acquisition
Featured snippet answer: Incumbents win through reliability and channel access; entrants win only with proven manufacturing quality and a cost structure that survives price compression.
Scenario A: Incumbent defending share
- Tactics:
- Ensure supply continuity and stable QA release rates
- Win pharmacy and health system contracts based on net price and fill-rate performance
- Manage labeling clarity for contraindications and split-dose instructions
- Financial profile: stable revenue, lower growth rates, sensitivity to raw material and regulatory events.
Scenario B: New generic entrant
- Tactics:
- Overbuild QA and validation to avoid lot rejections and recalls
- Target specific channels with favorable contract terms (high-throughput GI centers)
- Differentiate via kit experience (instructions, dosing regimen usability) if allowable
- Financial profile: higher upfront capex and ramp risk; returns depend on obtaining formulary access quickly.
Scenario C: Acquisition of a manufacturable niche platform
- Targets:
- Underutilized manufacturing assets with validated capability for electrolyte solutions
- Brands or SKUs with consistent demand and stable contracting
- Value creation:
- Cost reduction through manufacturing efficiency
- Margin improvement via contract renegotiation and reduced waste/returns
- Financial profile: deal-dependent, with integration and regulatory continuity risk.
Commercial fundamentals: revenue drivers, unit economics, and sensitivity
Featured snippet answer: In this category, revenue is unit-volume and contract-driven; profitability is determined by manufacturing COGS, QA and compliance costs, and rebate/chargeback structure.
What drives demand volume
- Procedure volumes and scheduling patterns
- Patient adherence trends
- Replacement behavior across bowel prep classes
What drives unit economics
- Manufacturing yield, stability losses, and scrap rates
- Packaging material costs and logistics
- Net price after rebates, wholesaler spreads, and payer terms
- Recall/liability risk costs as expected-value charges
Sensitivity analysis to include in a model
- Net price: most sensitive in highly genericized markets
- Fill rate: sensitivity to lost contract performance
- QA/inspection events: rare but high impact
- Commodity inputs: electrolytes and related supply chain fluctuations
Geographic considerations: where is the product most attractive?
Featured snippet answer: Attractiveness tracks where reimbursement is stable, manufacturing scale is feasible, and regulatory enforcement is predictable.
Typical geographic patterns
- Mature markets: dense competition, limited pricing upside, high compliance overhead.
- Emerging markets: sometimes less competitive, but higher regulatory and supply chain execution risk.
Investment implication
- Prefer regions where contracting supports sustainable pricing and where manufacturing quality systems can pass inspection without chronic remediation costs.
Key decision checklist for investors and acquirers
Featured snippet answer: Favor platforms with (1) verified manufacturing consistency, (2) strong distribution relationships, and (3) defensible channel placement; de-emphasize pure IP as the primary value driver.
Must-have diligence items
- Manufacturing: batch release consistency, impurity trends, and CAPA maturity
- Regulatory: inspection history and quality system robustness
- Commercial: contract coverage, rebate obligations, and formulary status
- Supply chain: single-source risks for key materials and packaging
- Product performance: complaint rates, adverse-event summaries, and rework/returns
Key Takeaways
- Sodium sulfate, magnesium sulfate and potassium chloride bowel prep is a commodity small-molecule category where investment returns depend more on manufacturing execution and contract positioning than on enduring exclusivity.
- Patent estates are typically limited in scope and remaining term, making growth reliant on scale, reliability, and distribution rather than IP monetization.
- The highest-risk levers are regulatory and quality-driven supply interruptions, not generic entry blocking.
- Best investment setups emphasize supply continuity, net pricing discipline, and QA-driven stability over exclusivity-dependent strategies.
FAQs
1) Is sodium sulfate, magnesium sulfate and potassium chloride considered an OTC product or prescription-only in major markets?
Demand and channel strategy depend on local approval status and labeling; investment models must reflect whether retail pharmacy substitution differs from health system procurement.
2) What adverse events most influence clinician acceptance for this class of bowel preps?
Clinician behavior is driven by tolerability, electrolyte disturbance management, and contraindication adherence in higher-risk patients.
3) How do split-dose regimens affect market outcomes for bowel prep solutions?
Split-dose instruction quality affects adherence and procedural completion, which in turn drives formulary and clinician preference.
4) What manufacturing quality metrics most predict recall risk for electrolyte bowel prep products?
Batch-to-batch impurity control, dissolution/potency consistency, and stability under real-world storage conditions are central to risk.
5) Can new formulation formats (kit design, dosing instructions) create durable differentiation?
Differentiation can improve adoption but usually does not create lasting exclusivity; durability depends on contracting and operational performance.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA. (FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Guidance for Industry: Content and Format of Chemistry, Manufacturing, and Controls Information for a Therapeutic Biological Product. (FDA). https://www.fda.gov/regulatory-information/search-fda-guidance-documents
More… ↓
